Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Omeprazole

FDA-approved product (capsule, delayed rel pellets, oral), marketed as Omeprazole, Prilosec, Omeprazole Magnesium and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Omeprazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Duodenal ulcer
  • Dyspepsia
  • Esophagitis
  • Gastric ulcer
  • Gastroesophageal reflux disease
  • Infection
  • Peptic ulcer
  • Peptic ulcer disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Proton pump inhibitors
FDA pharmacologic class
Proton Pump Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Omeprazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Omeprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19

    NCT04834752 · start 2021-05-01

    Registered record
    Registry ID
    NCT04834752
    Conditions
    COVID-19
    Interventions
    No intervention (Retrospective Cohort Observational)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-05-01
    Completion
    2021-12-31
    Enrolment
    400,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionNo intervention (Retrospective Cohort Observational)
    PhaseNot recorded
    Registry statusCompleted

  • A Study of LY3484356 in Healthy Female Participants

    NCT04840888 · start 2021-04-26

    Registered record
    Registry ID
    NCT04840888
    Conditions
    Healthy
    Interventions
    LY3484356; Omeprazole; Itraconazole; Carbamazepine; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-04-26
    Completion
    2022-04-12
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLY3484356; Omeprazole; Itraconazole; Carbamazepine +1 more
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers

    NCT04568772 · start 2020-11-25

    Registered record
    Registry ID
    NCT04568772
    Conditions
    Gastroesophageal Reflux Disease
    Interventions
    Atovaquone / Proguanil 250/100 mg; Tegoprazan 50 mg; Esomeprazole 40 mg; Vonoprazan 20 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-11-25
    Completion
    2021-08-03
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease
    InterventionAtovaquone / Proguanil 250/100 mg; Tegoprazan 50 mg; Esomeprazole 40 mg; Vonoprazan 20 mg
    PhasePhase 1
    Registry statusCompleted

  • Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes

    NCT04504045 · start 2020-09-01

    Registered record
    Registry ID
    NCT04504045
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Metformin; Caffeine; Efavirenz; Losartan; Omeprazol; Metoprolol; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-09-01
    Completion
    2022-05-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionMetformin; Caffeine; Efavirenz; Losartan +3 more
    PhasePhase 1
    Registry statusTerminated

  • Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

    NCT04282954 · start 2019-11-15

    Registered record
    Registry ID
    NCT04282954
    Conditions
    GERD
    Interventions
    JP-1366; JP-1366 placebo; Esomeprazole 40mg; Esomeprazole placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-11-15
    Completion
    2020-12-11
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGERD
    InterventionJP-1366; JP-1366 placebo; Esomeprazole 40mg; Esomeprazole placebo
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of HIP1601 Capsule

    NCT04080726 · start 2018-10-25

    Registered record
    Registry ID
    NCT04080726
    Conditions
    Erosive Gastroesophageal Reflux Disease
    Interventions
    HIP1601; HGP1705; HIP1601 Placebo; HGP1705 Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-10-25
    Completion
    2019-12-03
    Enrolment
    213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErosive Gastroesophageal Reflux Disease
    InterventionHIP1601; HGP1705; HIP1601 Placebo; HGP1705 Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects

    NCT02957474 · start 2016-11

    Registered record
    Registry ID
    NCT02957474
    Conditions
    Healthy Volunteers
    Interventions
    GED-0301; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-11
    Completion
    2016-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionGED-0301; Omeprazole
    PhasePhase 1
    Registry statusCompleted

  • MetAbolism vaRiability of VEnLafaxine

    NCT02590185 · start 2015-12

    Registered record
    Registry ID
    NCT02590185
    Conditions
    Major Depressive Disorders
    Interventions
    cocktail probe drugs
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-12
    Completion
    2020-04
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorders
    Interventioncocktail probe drugs
    PhaseNot applicable
    Registry statusUnknown

  • Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

    NCT02647086 · start 2015-12

    Registered record
    Registry ID
    NCT02647086
    Conditions
    Atopic Dermatitis
    Interventions
    Dupilumab; Midazolam; Omeprazole; Warfarin; Caffeine; Metoprolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-12
    Completion
    2016-07
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionDupilumab; Midazolam; Omeprazole; Warfarin +2 more
    PhasePhase 1
    Registry statusCompleted

  • Dabigatran in an Interaction Probe Drug Cocktail

    NCT02361619 · start 2015-02

    Registered record
    Registry ID
    NCT02361619
    Conditions
    Healthy Volunteers
    Interventions
    Caffeine; Diclofenac; Esomeprazole; Metoprolol; Midazolam; Dabigatran; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-02
    Completion
    2017-06
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionCaffeine; Diclofenac; Esomeprazole; Metoprolol +3 more
    PhasePhase 1
    Registry statusCompleted

  • Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients

    NCT03362281 · start 2014-10

    Registered record
    Registry ID
    NCT03362281
    Conditions
    Peptic Ulcer Hemorrhage
    Interventions
    Ilaprazole; Omeprazole; Ilaprazole tablet; amoxicillin and clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10
    Completion
    2015-04
    Enrolment
    540

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeptic Ulcer Hemorrhage
    InterventionIlaprazole; Omeprazole; Ilaprazole tablet; amoxicillin and clarithromycin
    PhasePhase 3
    Registry statusCompleted

  • Acid Pocket: Position and Aspiration

    NCT02199002 · start 2014-07

    Registered record
    Registry ID
    NCT02199002
    Conditions
    GERD - PPI Responders; GERD - PPI Non-responders; Barrett Esophagus; Healthy Volunteers
    Interventions
    multi-pH-impedance manometry catheter
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-07
    Completion
    2017-12-31
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGERD - PPI Responders; GERD - PPI Non-responders; Barrett Esophagus; Healthy Volunteers
    Interventionmulti-pH-impedance manometry catheter
    PhaseNot applicable
    Registry statusCompleted

  • Evaluation of the Prophylactic Use of Omeprazole in Patients Admitted to the State Hospital of Américo Brasiliense

    NCT02278432 · start 2014-06

    Registered record
    Registry ID
    NCT02278432
    Conditions
    Omeprazole
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-06
    Completion
    2015-10
    Enrolment
    427

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOmeprazole
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide

    NCT02090738 · start 2014-03

    Registered record
    Registry ID
    NCT02090738
    Conditions
    H. Pylori Infection
    Interventions
    Acetazolamide group; Standard regimen group
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2014-03
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionH. Pylori Infection
    InterventionAcetazolamide group; Standard regimen group
    PhasePhase 2
    Registry statusWithdrawn

  • A Study of Baricitinib and Omeprazole in Healthy Participants

    NCT01925144 · start 2013-10

    Registered record
    Registry ID
    NCT01925144
    Conditions
    Healthy Volunteers
    Interventions
    Baricitinib; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10
    Completion
    2013-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBaricitinib; Omeprazole
    PhasePhase 1
    Registry statusCompleted